Date: 2013-01-03
Type of information: R&D agreement
Compound: iPSC-derived human cells
Company: Cellular Dynamics (USA) AstraZeneca (UK)
Therapeutic area:
Type agreement: R&D
Action mechanism: iPSC technology, based on reprogramming adult cells from a simple blood sample or a skin biopsy to a pluripotent stem cell state, shows promise in delivering robust human cell models of high utility in drug discovery and without the ethical concerns linked to the use of human embryonic stem cells.
Disease:
Details:
Financial terms: Financial terms of the agreement were undisclosed.
Latest news:
